Finding new weight loss pills can help reduce diabetes risk by 80%

A new weight-loss drug capable of reducing the risk of diabetes by up to 80% is receiving the attention of the medical community globally.

According to information published in the Lancet Journal, a new study has shown that a weight-loss drug, scientifically named Liraglutide, is 3.0 mg in combination with a reasonable diet. , science, regular exercise can reduce the risk of diabetes by up to 80% in obese or more diabetic patients.

1. Belly fat will disappear after 2 weeks, if you drink this glass in the morning

The results of international clinical trials show that Liraglutide 3.0 mg dosage has the ability to promote interaction with areas that control brain appetite and energize the body.

The results show that, if three years of continuous treatment with Liraglutide 3.0 mg weight loss drug combined with a diet, exercise science will reduce the risk of developing type 2 diabetes.

In fact, this drug and combination therapies have reversed at least 60% of blood sugar levels back to normal levels. Research indicates.

" Liraglutide promotes weight loss by activating the brain regions to control appetite and people feel fuller and less likely to eat and this causes the blood sugar levels to rise from food and drink to decrease. and blood sugar quickly returned to balance, 'said Carel Le Roux, a professor at Imperial College London in a statement.

' Although it is famous for being used only for weight loss, however, the ability to reverse high sugar levels in the blood, to help prevent sugar loss and diet, to exercise reasonably is a major breakthrough in medicine. - Carel Le Roux added.

Among patients who have diabetes, when taken with Liraglutide, the time to develop and increase blood sugar will be three times longer than those without diabetes.

In addition, Liraglutide also helps patients lose 7% more body weight than 2% in obese groups using placebo - the researchers said.

" Liraglutide 3.0 mg can provide us with a new treatment for obese and diabetic patients " - John Wilding, professor at the University of Liverpool added.